Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Contributor

Peter Kraemer, Ph.D.

Peter Kraemer, Ph.D. ([email protected]), is responsible for directing technical projects, chemistry and biotech development, and large-scale fermentation at Sanofi.

More GEN Content From This Contributor:

GEN Articles

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »